Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Q2 Results 2026 (FY27) investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.
Get Symbiotec Pharmalab Ltd's next results in your feed
Guidance rank: #24 of 85 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Symbiotec Pharmalab Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q2 FY27 consolidated revenue from operations: Rs. 280 Cr, up 43% YoY from Rs. 196 Cr in Q2 FY26 (Page 9). Q2 FY27 Financials (Page 9):.
From Symbiotec Pharmalab Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.
How did Symbiotec Pharmalab's revenue grow in the September 2026 quarter?
2 more points from Symbiotec Pharmalab Ltd's call on revenue
Create a free account to keep reading this call
What happened to Symbiotec Pharmalab's margins in Q2 FY27?
See what Symbiotec Pharmalab Ltd said on profitability & margins — free account, 30 seconds.
What capex is Symbiotec Pharmalab planning?
- Total Gross Capex as of Sept 30, 2026: ₹1,509 Cr; Estimated by end FY27: ₹1,672 Cr (Page 8)
- Capex Breakdown:
- Existing API Business (Steroids & Hormones): ₹649 Cr (39% of total), generating revenue
- Complex Injectables (Dual Chamber Vials): ₹357 Cr (currently), estimated ₹377 Cr by FY27 end (61% of total), majority capacity reserved with strategic partner; revenue expected in 6-12 months
- CDMO Services (400 KL + 14 KL): ₹492 Cr (current), estimated ₹584 Cr by FY27 end; take-or-pay customer arrangements in place
- New API Capex: ₹12 Cr current; ₹63 Cr estimated (Page 8)
- New biologics facility (14 KL capacity) under construction at Ujjain (Page 20)
- Biotech plant expansion at SEZ, Pithampur (280 KL capacity) and commissioned biomanufacturing at Ujjain (400 KL) (Page 20)
2 more points from Symbiotec Pharmalab Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Is Symbiotec Pharmalab raising money or cutting debt?
See what Symbiotec Pharmalab Ltd said on fundraising & capital structure — free account, 30 seconds.
How big is Symbiotec Pharmalab's order book?
See what Symbiotec Pharmalab Ltd said on order book & pipeline — free account, 30 seconds.
Symbiotec Pharmalab Ltd — Quarterly revenue & net profit
Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹218 Cr, net profit ₹14 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Symbiotec Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Hester Bios (Q2 FY27)
Standalone Q2 FY27 revenue: INR 829.28 million, up 28% YoY (from INR 645.79 million in Q2 FY26). Key results statement takeaways from Hester Biosciences Ltd's Q
- Glenmark Pharmaceuticals (Q2 FY27)
42,473 million, down 29.8% YoY. Key investor presentation takeaways from Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation — and how it ranks against
- Windlas Biotech (Q2 FY27)
264 Cr, a 19% YoY increase from Rs. Key investor presentation takeaways from Windlas Biotech Ltd's Q2 FY27 investor presentation — and how it ranks against sect
- Rubicon Research Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10). Key investor presentation takeaways
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Symbiotec Pharmalab Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Symbiotec Pharmalab Ltd Q2 FY27 results?
Q2 FY27 consolidated revenue from operations: Rs. 280 Cr, up 43% YoY from Rs. 196 Cr in Q2 FY26 (Page 9). Q2 FY27 Financials (Page 9):.
What is Symbiotec Pharmalab Ltd share price analysis?
Symbiotec Pharmalab Ltd currently shows a neutral. The stock trades at a P/E of 82.1 with a market cap of ₹8,170 Cr. Investors should review the full earnings analysis for detailed insights.
Is Symbiotec Pharmalab Ltd planning capital expenditure?
Total Gross Capex as of Sept 30, 2026: ₹1,509 Cr; Estimated by end FY27: ₹1,672 Cr (Page 8).
Keep Symbiotec Pharmalab Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.